title: Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
abstract: There are no systematic data regarding nonmaintained induction for those patients with multiple myeloma (MM) who do not receive consolidative autologous stem cell transplantation. Of 173 patients with newly diagnosed MM treated with lenalidomide and dexamethasone (LenDex) as primary therapy, 31 patients had their lenalidomide discontinued for reasons other than progression or alternate therapy. Median progression free survival (PFS) from the time of discontinuing lenalidomide was longer in patients who received lenalidomide ≥ 1 year (39 vs. 13 months, P < 0.05); there was no difference in PFS for those treated for 1-2 years as compared to ≥ 2 years. Among those taking lenalidomide for ≥ 1 year PFS was superior in patients who were in very good partial response (VGPR) or better as compared to those with partial response (48.4 versus 14.8 months, P < 0.05). All patients who progressed and were rechallenged with LenDex responded. These analyses illustrate that discontinuation of lenalidomide after 1 year among those patients achieving a ≥VGPR can result in long-term disease control.
authors.affiliation: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
authors.forename: Taxiarchis V
authors.initials: TV
authors.lastname: Kourelis
authors.forename: Shaji K
authors.initials: SK
authors.lastname: Kumar
authors.forename: Geetika
authors.initials: G
authors.lastname: Srivastava
authors.forename: Morie A
authors.initials: MA
authors.lastname: Gertz
authors.forename: Martha Q
authors.initials: MQ
authors.lastname: Lacy
authors.forename: Francis K
authors.initials: FK
authors.lastname: Buadi
authors.forename: Suzanne R
authors.initials: SR
authors.lastname: Hayman
authors.forename: Steven R
authors.initials: SR
authors.lastname: Zeldenrust
authors.forename: Nelson
authors.initials: N
authors.lastname: Leung
authors.forename: Robert A
authors.initials: RA
authors.lastname: Kyle
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Russell
authors.forename: David
authors.initials: D
authors.lastname: Dingli
authors.forename: John A
authors.initials: JA
authors.lastname: Lust
authors.forename: Yi
authors.initials: Y
authors.lastname: Lin
authors.forename: Prashant
authors.initials: P
authors.lastname: Kapoor
authors.forename: Ronald
authors.initials: R
authors.lastname: Go
authors.forename: S Vincent
authors.initials: SV
authors.lastname: Rajkumar
authors.forename: Angela
authors.initials: A
authors.lastname: Dispenzieri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D018450:Disease Progression; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016896:Treatment Outcome; D028761:Withholding Treatment
chemical_list: D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide